R Raman
Overview
Explore the profile of R Raman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
278
Citations
2636
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghosh S, Laxmaiah A, Chandak G, Meshram I, Raman R, Sengupta S, et al.
Eur J Clin Nutr
. 2025 Jan;
PMID: 39779946
Background: Surveys based on capillary blood show that anaemia is rampant in India, but capillary blood haemoglobin (Hb) may not accurately reflect venous blood Hb concentrations. Further, iron deficiency (ID)...
2.
Dabiri S, Raman R, Grooms J, Molina-Henry D
J Prev Alzheimers Dis
. 2024 Nov;
11(6):1647-1672.
PMID: 39559877
Background: Despite higher dementia prevalence in racial and ethnic minoritized communities, they are underrepresented in Alzheimer's disease clinical trials. Community-based recruitment strategies are believed to yield positive outcomes in various...
3.
Ritchie M, Raman R, Ernstrom K, Wang S, Donohue M, Aisen P, et al.
J Prev Alzheimers Dis
. 2024 Nov;
11(6):1563-1571.
PMID: 39559869
Background: Many cognitively unimpaired older adults are interested in learning their Alzheimer's disease (AD) biomarker status, but little is known about motivations to undergo biomarker testing and result disclosure in...
4.
Walter S, Langford O, Jimenez-Maggiora G, Abdel-Latif S, Rissman R, Grill J, et al.
J Prev Alzheimers Dis
. 2024 Oct;
11(5):1435-1444.
PMID: 39350391
Background: Advances in plasma biomarkers to detect Alzheimer's disease (AD) biology allows researchers to improve the efficiency of participant recruitment into preclinical trials. Recently, protein levels of plasma amyloid-beta and...
5.
Rentz D, Grill J, Molina-Henry D, Jicha G, Rafii M, Liu A, et al.
J Prev Alzheimers Dis
. 2024 Oct;
11(5):1418-1425.
PMID: 39350389
Introduction: Metrics of a participant's socioeconomic status (SES) are not routinely collected or standardized in clinical trials. This omission limits the ability to evaluate the generalizability of trial results and...
6.
Raman R, Hussen K, Donohue M, Ernstrom K, Holdridge K, Langford O, et al.
J Prev Alzheimers Dis
. 2024 Jul;
11(4):874-880.
PMID: 39044496
Background: Participant discontinuation from study treatment in a clinical trial can leave a trial underpowered, produce bias in statistical analysis, and limit interpretability of study results. Retaining participants in clinical...
7.
Shirzadi Z, Schultz A, Properzi M, Yaari R, Yau W, Brickman A, et al.
J Prev Alzheimers Dis
. 2024 Jul;
11(4):869-873.
PMID: 39044495
Background: Increased white matter hyperintensity (WMH) volume visible on MRI is a common finding in Alzheimer's disease (AD). We hypothesized that WMH in preclinical AD is associated with the presence...
8.
Molina-Henry D, Langford O, Donohue M, Raman R, Aisen P, Johnson K, et al.
J Prev Alzheimers Dis
. 2024 Jul;
11(4):831-837.
PMID: 39044491
Background: Individuals from diverse racial and ethnic groups are severely underrepresented in Alzheimer's disease trials in part due to disproportionate biomarker ineligibility. Evidence from recent studies support plasma phosphorylated tau...
9.
Rissman R, Donohue M, Langford O, Raman R, Abdel-Latif S, Yaari R, et al.
J Prev Alzheimers Dis
. 2024 Jul;
11(4):823-830.
PMID: 39044490
Background: Blood-based AD biomarkers such as plasma P-tau217 are increasingly used in clinical trials as a screening tool. Objectives: To assess the utility of an electrochemiluminescence (ECL) immunoassay in predicting...
10.
Rentz D, Rosenberg P, Sperling R, Donohue M, Raman R, Liu A, et al.
J Prev Alzheimers Dis
. 2024 Jul;
11(4):814-822.
PMID: 39044489
Background: Clinical Dementia Rating (CDR) global (CDR-G) and sum of box scores (CDR-SB) are commonly used as primary outcome variables to measure progression or treatment effects in symptomatic Alzheimer disease...